TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25226857
Drug: IVF for
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Study: 25226857
Drug: Basal FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal FSH of 10-15 mIU/mL and E2≥40 pg/mL
Study: 23756586
Drug: Walnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-enriched diet (56 g of walnuts daily)
Study: 19834690
Drug: Apomorphine sublingually
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingually (2 mg)
Study: 19834690
Drug: Apomorphine subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine subcutaneously (0.005 mg/kg)
Study: 17654304
Drug: INS50589 (0.1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS50589 (0.1-3 mg/kg/h for four hours)
Study: 13129878
Drug: Routine users
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine users of aspirin
Study: 13129878
Drug: Routine users
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine users of warfarin
Study: 13129878
Drug: Discontinued aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued aspirin use
Study: 13129878
Drug: Discontinued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued warfarin use
Study: 13129878
Drug: Routine continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine continuous users of aspirin
Study: 13129878
Drug: Routine continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine continuous users of warfarin
Study: 10383509
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg b.d.
Study: 2066053
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (500 mg t.i.d.)
Study: 6316289
Drug: Ketoconazole treatment
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole treatment (daily doses ranged from 3 to 13 mg/Kg, treatment period from 7 days to 14 months)
Study: 29374667
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine infusion
Study: 29374667
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural infusion
Study: 27253224
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) alone or in combination with chemo- and/or radiotherapy
Study: 16248236
Drug: Maiwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maiwei Dihuang Oral Liquid (MDOL) 10 ml twice daily for 3 months
Study: 16248236
Drug: Prednisone initial
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone initial dose of 0.5-1 mg/kg, reduced conditionally over 6-8 weeks
Study: 10971320
Drug: Clindamycin 1%/tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1%/tretinoin 0.025% gel (CTG; Velac) applied once daily
Study: 10971320
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% lotion (CLN; Dalacin T) applied twice daily
Study: 1518664
Drug: Cimetidine (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (7-day administration)
Study: 1518664
Drug: Famotidine (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (7-day administration)
Study: 31645451
Drug: etokimab (ANB020),
Approvals — FDA: no, EMA: no, PMDA: no
Description: etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody, single systemic administration
Study: 23839157
Drug: Attenuated RIX4414
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated RIX4414 human rotavirus vaccine
Study: 18650162
Drug: Observation/no adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation/no adjuvant chemotherapy
Study: 16569044
Drug: Lyc‐o‐Mato (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyc‐o‐Mato (5.7 mg of lycopene, 3.7 mg of phytoene, 2.7 mg of phytofluene, 1 mg of beta‐carotene, and 1.8 mg of alpha‐tocopherol)
Study: 16569044
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (same taste and flavor, but devoid of active compounds)
Study: 12518122
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate patch (15 mg)
Study: 11144400
Drug: Cefdinir 7
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 7 mg/kg twice daily or 14 mg/kg once daily for 10 days or 7 mg/kg twice daily for 5 days
Study: 11144400
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 10 mg/kg 4 times daily for 10 days
Study: 9301496
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg twice daily alone (RBC400)
Study: 9301496
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC400+CLAR)
Study: 9301496
Drug: RBC 800
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 800 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC800+CLAR)
Study: 8472526
Drug: Cisapride effervescent
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride effervescent granules (3 sachets daily for 8 weeks)
Study: 8472526
Drug: Metoclopramide-dimeticone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide-dimeticone combination (3 sachets daily for 8 weeks)
Study: 8472526
Drug: Metoclopramide-dimeticone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide-dimeticone combination
Study: 24430917
Drug: Nabiximols (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (maximum daily dose, 86.4 mg of Δ9‐tetrahydrocannabinol and 80 mg of cannabidiol)
Study: 16416357
Drug: Lead exposure
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead exposure (mean PbB 5.4 microg Pb/100 ml)
Study: 16416357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean PbB 4.7 microg Pb/100 ml)
Study: 12391100
Drug: (13)C‐enriched 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: (13)C‐enriched 6% CHO(exo) beverage (total volume per trial: 24 ml/kg)
Study: 10571596
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus topical mesalazine (2.4 g/day oral + 4 g/day topical)
Study: 10571596
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (2.4 g/day)
Study: 8687366
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo (group treatment)
Study: 8687366
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy followed by exposure in vivo (group treatment)
Study: 8687366
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment (integrated from the start, group treatment)
Study: 8687366
Drug: Individual treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatments
Study: 2065622
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid (AA) solution
Study: 29669780
Drug: Torsional phacoemulsification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsional phacoemulsification with adjunctive endocapsular nuclear fragmentation using a manual microinterventional nitinol filament loop device (miLOOP)
Study: 28728606
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (1200 mg/day)
Study: 24860124
Drug: 4% succinylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% succinylated gelatin (Gelofusine, GEL group, n = 40)
Study: 9423999
Drug: Single 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 Gy treatment
Study: 3541803
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + M (400 mg of doxycycline + 1500 mg of metronidazole)
Study: 3541803
Drug: D (400
Normalized name: True Folic Acid (400mcg) 667mcg DFE Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: D (400 mg of doxycycline)
Study: 11388526
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg
Study: 11388526
Drug: Ropivacaine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 30 mg
Study: 11388526
Drug: Ropivacaine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 40 mg
Study: 11388526
Drug: Ropivacaine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 50 mg
Study: 30643223
Drug: Isocaloric standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric standard treatment for 12 weeks
Study: 29480843
Drug: Routine primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine primary therapy (Control)
Study: 24465570
Drug: PHiD-CV (10-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine)
Study: 22228773
Drug: fenofibrate/pravastatin 160/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate/pravastatin 160/40 mg plus ezetimibe 10 mg (triple therapy)
Study: 22228773
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg plus ezetimibe 10 mg (dual therapy)
Study: 12107720
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (1 mU/kg per min for 60 min) during adenosine infusion (140 microg/kg per min i.v.)
Study: 12107720
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (140 microg/kg per min i.v.) without insulin
Study: 12107720
Drug: Normoglycaemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemia (plasma glucose 6 mmol/l)
Study: 10430967
Drug: Hemodialysis patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis patients receiving antihypertensive therapy.
Study: 8699846
Drug: Pentoxifylline 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 1,200 mg daily for 2 months
Study: 2347957
Drug: Aspartame (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (15 mg/kg body weight)
Study: 379366
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with tetracycline
Study: 28570250
Drug: NPWTi with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWTi with 0.125% sodium hypochlorite solution
Study: 26267728
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate gel
Study: 10422491
Drug: no hypolipemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: no hypolipemic medication
Study: 7999482
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion (group A: 1.25 u.h‐1)
Study: 2897785
Drug: Somatostatin (SRIF)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SRIF) infusion (500 micrograms/h) for 90 min before and 5 h after a protein meal (240 g of meat)
Study: 21059836
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (5 g/d)
Study: 21059836
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (10 g/d)
Study: 21059836
Drug: rhGH (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (3 μg/kg/d)
Study: 21059836
Drug: rhGH (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (5 μg/kg/d)
Study: 21059836
Drug: Co-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment with rhGH
Study: 21059836
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in testosterone and insulin‐like growth factor 1 levels
Study: 14669258
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (black seed oil) at a dose of 40 to 80 mg/kg/day
Study: 9085939
Drug: Plasma IL-1
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma IL-1 receptor antagonist and IL-10 levels
Study: 1493941
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GM-CSF treatment)
Study: 27890522
Drug: Tamsulosin (alpha-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (alpha-adrenergic blocker)
Study: 17264337
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6) and Paclitaxel (200 mg/m2 every 3 weeks)
Study: 17264337
Drug: Gemcitabine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1 g/m2 days 1 and 8) and Cisplatin (60 mg/m2 day 1 every 3 weeks)
Study: 12933419
Drug: IT fentanyl
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT fentanyl 25 micro g and hyperbaric bupivacaine 2.5 mg (Group H)
Study: 12933419
Drug: IT fentanyl
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT fentanyl 25 micro g and plain bupivacaine 2.5 mg (Group P)
Study: 10407502
Drug: LDL-apheresis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis and drugs
Study: 1810257
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (1000 mg orally)
Study: 29024278
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic bumetanide
Study: 15680453
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment (medical treatment, with later evacuation allowed if necessary)
Study: 12922086
Drug: New pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pediatric tick-borne encephalitis (TBE) vaccine
Study: 10669065
Drug: Daily combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily combination tablet administration (8 mg buprenorphine + 2 mg naloxone)
Study: 10669065
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg alternate-day buprenorphine administration
Study: 10669065
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg alternate-day buprenorphine administration
Study: 10669065
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on interposed day during alternate-day treatment
Study: 8797613
Drug: Low-dose anti-tumor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anti-tumor necrosis factor therapy
Study: 8797613
Drug: High-dose anti-tumor
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anti-tumor necrosis factor therapy
Study: 1632683
Drug: Single donor-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single donor-specific transfusion (DST) 24 to 48 hours before transplant with intravenous cyclosporine initiated after transfusion
Study: 6208968
Drug: Banked breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banked breast milk or maternal milk supplement
Study: 30641007
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC), 0.5 g per pill, 3 pills each time, three times per day for 12 weeks
Study: 30641007
Drug: Sulfasalazine (SASP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 12 weeks
Study: 22124360
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (1110 MBq)
Study: 20556834
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/d)
Study: 6753887
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide phosphate (loading dose 150, 200, or 300 mg followed by 100, 150, or 200 mg every 6 hours based on weight)
Study: 25858261
Drug: Doxycycline (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (oral, twice daily for 7 days)
Study: 21142946
Drug: Soymilk (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk (500 mL daily for 21 days)
Study: 19172254
Drug: Allicin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicin (180 mg capsule once daily for 14 days)
Study: 16728906
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral risperidone and 2 mg IM lorazepam
Study: 16728906
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral haloperidol and 2 mg IM lorazepam
Study: 16728906
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo and 2 mg IM lorazepam
Study: 11334901
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 17‐beta
Study: 8322566
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg methadone
Study: 8322566
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diamorphine
Study: 30883839
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 5.25 mg/kg
Study: 28140753
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (both dosages)
Study: 26402703
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection of 50 U
Study: 26402703
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection of 100 U
Study: 26402703
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection of 200 U
Study: 14970982
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (alone or in combination with other therapies)
Study: 11694607
Drug: Full-strength tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength tea (15 g)
Study: 11694607
Drug: Caffeinated water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated water (270 mg caffeine)
Study: 11694607
Drug: Half-strength tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength tea (7.5 g)
Study: 856049
Drug: Betamethasone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.1% as valerate in an ointment base
Study: 27816035
Drug: Four sessions
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four sessions of smoking cessation counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Study: 27816035
Drug: No counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Study: 25378648
Drug: Docetaxel 20
Normalized name: docetaxel 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 20 mg/m² plus cisplatin 25 mg/m² on Day 1, 8, and 15 (docetaxel plus cisplatin)
Study: 25378648
Drug: Docetaxel 25
Normalized name: docetaxel 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 25 mg/m² on the same schedule (docetaxel)
Study: 17317857
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg)
Study: 23572137
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg) in combination with intermediate-dose cytarabine (200 mg/m2 for 7 days)
Study: 16616232
Drug: Lipo-ecraprost (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo-ecraprost (60 microg, administered intravenously on each of 5 days per week for 8 weeks)
Study: 7962654
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose cyclosporin plus nifedipine
Study: 7962654
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose cyclosporin
Study: 7962654
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin plus azathioprine
Study: 3296733
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg i.v. bolus, then 20 mg/h by infusion for 4 h (low-dose continuous infusion metoclopramide)
Study: 3296733
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg i.v. bolus every 2 h for three doses (high-dose bolus metoclopramide)
Study: 29020355
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 or 25 mg once daily
Study: 20594207
Drug: Community Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Control (CC)
Study: 19064521
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (2.5 mg folic acid/d, 50 mg vitamin B‐6/d, and 1 mg vitamin B‐12/d)
Study: 8645503
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg eugenol for 7 days
Study: 7515704
Drug: High-dose thrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thrombin time (HITT)